Download or read book Oral Contraceptives and Breast Cancer written by Institute of Medicine and published by National Academies Press. This book was released on 1991-02-01 with total page 196 pages. Available in PDF, EPUB and Kindle. Book excerpt: At least 10.7 million American women use oral contraceptives (OCs). The potential connection with breast cancer has caused concern among these OC users and uncertainty among many of their physicians. This new volume offers the most up-to-date information available on this critical topic. While the best available knowledge does not support any fundamental change in clinical practice with respect to the use of OCs, this book offers specific recommendations for more research to fully resolve the relationship between OCs and breast cancer. Noting consumer confusion, the volume includes a concise summary of benefits, risks, and other practical information for contraceptive users and their doctors. The volume presents current data on changes in patterns of OC use, differences in risk at different ages, the benefits of OCs, and more. Oral Contraceptives and Breast Cancer will be important reading for obstetricians/gynecologists and other health professionals, their patients who use OCs, contraceptive manufacturers, women's health advocates, policymakers, and researchers.
Download or read book Hormonal Contraception and Post menopausal Hormonal Therapy written by IARC Working Group on the Evaluation of Carcinogenic Risks to Humans and published by World Health Organization. This book was released on 1999 with total page 692 pages. Available in PDF, EPUB and Kindle. Book excerpt: Evaluates evidence for an increased risk of cancer in women using combined oral contraceptives, progestogen-only hormonal contraceptives, post-menopausal estrogen therapy, and post-menopausal estrogen-progestogen therapy. Although the carcinogenicity of these preparations has been extensively investigated, the book stresses the many complex methodological issues that must be considered when interpreting findings and weighing results. Evidence of an association between use of these preparations and positive effects on health, including a reduced risk of some cancers, is also critically assessed. The first and most extensive monograph evaluates evidence of an association between the use of combined oral contraceptives and cancer at nine sites. Concerning breast cancer, the evaluation concludes that, even if the association is causal, the excess risk for breast cancer associated with patterns of use that are typical today is very small. Studies of predominantly high-dose preparations found an increased risk of hepatocellular carcinoma in the absence of hepatitis viruses. Citing these findings, the evaluation concludes that there is sufficient evidence in humans for the carcinogenicity of combined oral contraceptives. The evaluation also found sufficient evidence for the carcinogenicity of some, but not all, combined preparations in animals. Combined oral contraceptives were classified as carcinogenic to humans. The evaluation also cites conclusive evidence that these agents have a protective effect against cancers of the ovary and endometrium. Progestogen-only contraceptives are evaluated in the second monograph, which considers the association with cancer at six sites. The evaluation found no evidence of an increased risk for breast cancer. Although the evaluation found sufficient evidence in animals for the carcinogenicity of medroxyprogesterone acetate, evidence for the carcinogenicity of progestogen-only contraceptives in humans was judged inadequate. Progestogen-only contraceptives were classified as possibly carcinogenic to humans. The third monograph, on post-menopausal estrogen therapy, considers evidence of an association with cancer at eight sites. Findings from a large number of epidemiological studies indicate a small increase in the risk of breast cancer in women who have used these preparations for five years or more. Studies consistently show an association between use of post-menopausal estrogen therapy and an increased risk for endometrial cancer. Data on the association with other cancers were either inconclusive or suggested no effect on risk. The evaluation concludes that post-menopausal estrogen therapy is carcinogenic to humans. The final monograph evaluates the association between the use of post-menopausal estrogen-progestogen therapy and cancer at four sites. The evaluation of limited data on breast cancer found an increased relative risk observed with long-term use. Data were judged insufficient to assess the effects of past use and of different progestogen compounds, doses, and treatment schedules. For endometrial cancer, the evaluation found an increase in risk relative to non-users when the progestogen was added to the cycle for 10 days or fewer. Post-menopausal estrogen-progestogen therapy was classified as possibly carcinogenic to humans. Concerning post-menopausal therapy in general, the book notes that evidence of carcinogenic risks must be placed in perspective of potential benefits. The prevention of osteoporotic fractures is cited as the best-established benefit. Evidence also suggests that estrogen prevents heart disease and may prevent memory loss and dementia.
Download or read book Oral Contraceptives and Breast Cancer The Implications of the Present Findings for Informed Consent and Informed Choice written by R.D. Mann and published by CRC Press. This book was released on 1990-01-15 with total page 426 pages. Available in PDF, EPUB and Kindle. Book excerpt: A collection of the proceedings presented at the Royal Society of Medicine by American and European researchers involved in longterm studies on oral contraceptives. Topics include reviews of case-control studies on contraceptive use before the age of 25 or the first full-term pregnancy.
Download or read book Breast Cancer written by Chris Kahlenborn and published by One More Soul. This book was released on 2000 with total page 404 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Modern Oral Contraception written by Melinda Wallach and published by . This book was released on 2000 with total page 308 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Contraceptive Use and Controlled Fertility written by National Research Council and published by National Academies Press. This book was released on 1989-02-01 with total page 172 pages. Available in PDF, EPUB and Kindle. Book excerpt: These four papers supplement the book Contraception and Reproduction: Health Consequences for Women and Children in the Developing World by bringing together data and analyses that would otherwise be difficult to obtain in a single source. The topics addressed are an analysis of the relationship between maternal mortality and changing reproductive patterns; the risks and benefits of contraception; the effects of changing reproductive patterns on infant health; and the psychosocial consequences to women of controlled fertility and contraceptive use.
Download or read book Selected Practice Recommendations for Contraceptive Use written by World Health Organization. Reproductive Health and Research and published by World Health Organization. This book was released on 2005 with total page 144 pages. Available in PDF, EPUB and Kindle. Book excerpt: This document is one of two evidence-based cornerstones of the World Health Organization's (WHO) new initiative to develop and implement evidence-based guidelines for family planning. The first cornerstone, the Medical eligibility criteria for contraceptive use (third edition) published in 2004, provides guidance for who can use contraceptive methods safely. This document, the Selected practice recommendations for contraceptive use (second edition), provides guidance for how to use contraceptive methods safely and effectively once they are deemed to be medically appropriate. The recommendations contained in this document are the product of a process that culminated in an expert Working Group meeting held at the World Health Organization, Geneva, 13-16 April 2004.
Download or read book Study Finds No Link Between Breast Cancer and Oral Contraceptives written by and published by . This book was released on 1986 with total page 2 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book The Relationship Between Oral Contraceptives and Breast Cancer Risk written by Afsaneh Golshani and published by . This book was released on 2021 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: Breast cancer is the most common cancer in women worldwide. Studies have linked modifiable and non-modifiable risk factors to an increased diagnosis of breast cancer; however, having these risk factors does not mean the person will get the disease. Oral contraceptive use, among many other modifiable risk factors, have raised questions about the increase in risk it might bear in women of reproductive age. The oral contraceptive pill is currently the fourth most common contraceptive method worldwide used by over 150 million women daily. Recent data has shown evidence that use of oral contraceptives may have an increased risk of breast and cervical cancers, while risks of endometrial, ovarian, and colorectal cancers are reduced. This systematic review evaluated the literature for qualitative themes pertaining to the use of oral contraceptives with newer formulations and the impact on breast cancer risk. The aim of this research was to understand usage of birth control pills, length of use, and the specific formulation.
Download or read book Medical Eligibility Criteria for Contraceptive Use written by and published by World Health Organization. This book was released on 2010 with total page 130 pages. Available in PDF, EPUB and Kindle. Book excerpt: Medical Eligibility Criteria for Contraceptive Use reviews the medical eligibility criteria for use of contraception, offering guidance on the safety and use of different methods for women and men with specific characteristics or known medical conditions. The recommendations are based on systematic reviews of available clinical and epidemiological research. It is a companion guideline to Selected Practice Recommendations for Contraceptive Use. Together, these documents are intended to be used by policy-makers, program managers, and the scientific community to support national programs in the preparation of service delivery guidelines. The fourth edition of this useful resource supersedes previous editions, and has been fully updated and expanded. It includes over 86 new recommendations and 165 updates to recommendations in the previous edition. Guidance for populations with special needs is now provided, and a new annex details evidence on drug interactions from concomitant use of antiretroviral therapies and hormonal contraceptives. To assist users familiar with the third edition, new and updated recommendations are highlighted. Everyone involved in providing family planning services and contraception should have the fourth edition of Medical Eligibility Criteria for Contraceptive Use at hand.
Download or read book Current Contraceptive Status Among Women Aged 15 44 United States 2011 2013 written by Kimberly Daniels and published by . This book was released on 2014 with total page 12 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Clinical Gynecology written by Eric J. Bieber and published by Cambridge University Press. This book was released on 2015-04-23 with total page 1127 pages. Available in PDF, EPUB and Kindle. Book excerpt: Written with the busy practice in mind, this book delivers clinically focused, evidence-based gynecology guidance in a quick-reference format. It explores etiology, screening, tests, diagnosis, and treatment for a full range of gynecologic health issues. The coverage includes the full range of gynecologic malignancies, reproductive endocrinology and infertility, infectious diseases, urogynecologic problems, gynecologic concerns in children and adolescents, and surgical interventions including minimally invasive surgical procedures. Information is easy to find and absorb owing to the extensive use of full-color diagrams, algorithms, and illustrations. The new edition has been expanded to include aspects of gynecology important in international and resource-poor settings.
Download or read book Contraceptive Methods Women Have Ever Used United States 1982 2010 written by Kimberly Daniels and published by . This book was released on 2013 with total page 20 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Oral Contraceptives and the Risk of Breast Cancer written by Isabelle Romieu and published by . This book was released on 1989 with total page 83 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Oral Contraceptives and Breast Cancer written by and published by . This book was released on with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: The nonprofit corporation Colorado HealthSite presents a summary of the article "Risk of Breast Cancer With Oral Contraceptive Use in Women With a Family History of Breast Cancer" and the related editorial "Oral Contraceptives and Breast Cancer: A Note of Caution for High-Risk Women." The article and the editorial originally appeared in the October 11, 2000 issue of the "Journal of the American Medical Association (JAMA)."
Download or read book Chalk Talks in Internal Medicine written by Somnath Mookherjee and published by Springer Nature. This book was released on 2020-09-30 with total page 347 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides teaching scripts for medical educators in internal medicine and coaches them in creating their own teaching scripts. Every year, thousands of attending internists are asked to train the next generation of physicians to master a growing body of knowledge. Formal teaching time has become increasingly limited due to rising clinical workload, medical documentation requirements, duty hour restrictions, and other time pressures. In addition, today’s physicians-in-training expect teaching sessions that deliver focused, evidence-based content that is integrated into clinical workflow. In keeping with both time pressures and trainee expectations, academic internists must be prepared to effectively and efficiently teach important diagnostic and management concepts. A teaching script is a methodical and structured plan that aids in effective teaching. The teaching scripts in this book anticipate learners’ misconceptions, highlight a limited number of teaching points, provide evidence to support the teaching points, use strategies to engage the learners, and provide a cognitive scaffold for teaching the topic that the teacher can refine over time. All divisions of internal medicine (e.g. cardiology, rheumatology, and gastroenterology) are covered and a section on undifferentiated symptom-based presentations (e.g. fatigue, fever, and unintentional weight loss) is included. This book provides well-constructed teaching scripts for commonly encountered clinical scenarios, is authored by experienced academic internists and allows the reader to either implement them directly or modify them for their own use. Each teaching script is designed to be taught in 10-15 minutes, but can be easily adjusted by the reader for longer or shorter talks. Teaching Scripts in Internal Medicine is an ideal tool for internal medicine attending physicians and trainees, as well as physician’s assistants, nurse practitioners, and all others who teach and learn internal medicine.
Download or read book Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer written by U. S. Department of Health and Human Services and published by CreateSpace. This book was released on 2013-07 with total page 518 pages. Available in PDF, EPUB and Kindle. Book excerpt: Ovarian cancer is the eighth most common cancer in women and is the fifth leading cause of cancer death, with an age-adjusted rate of 8.2 deaths per 100,000 women. Given current age-specific incidence and demographic projections, the number of cases of ovarian cancer will almost double over the next 35 years as women born between 1946 and 1964 (“baby boom” generation) reach the age of highest incidence (60 years & older). While advances in surgery, chemotherapy, and radiation therapy over the past 20 years have led to improved outcomes, overall 5-year survival is only 42% for ovarian cancer compared with 88% for breast cancer and 63% for colorectal cancer. The high mortality rate in women with ovarian cancer is largely attributed to the later stage at presentation compared with other common cancers. This has led to intense research efforts to identify effective screening strategies for ovarian cancer, but results have been disappointing, particularly with regard to decreases in mortality. There is consistent evidence from a variety of sources that oral contraceptive (OC) use reduces ovarian cancer risk. This evidence includes declining age-specific ovarian cancer incidence and mortality in cohorts of women who had access to OCs throughout their reproductive life, and there are several biologically plausible mechanisms for a protective effect. The potential benefit of using OCs solely to reduce the risk of ovarian cancer must be weighed with knowledge of other potential noncontraceptive health benefits of OCs and potential harms. The combination of systematic review and decision-analytic modeling presented in this report allows us to estimate the tradeoff between the harms and benefits of OC use for the overall population and for individual women, accounting for the potential influence of other factors, such as timing of OC use or presence of risk factors such as family history. This report was funded by the Centers for Disease Control and Prevention in conjunction with the Agency for Healthcare Research and Quality, and was designed to evaluate the benefits and harms of the use of oral contraceptives as a primary preventive measure against ovarian cancer. We focused on synthesizing the available evidence for the effectiveness of this strategy in a general population and in groups at elevated risk. We also evaluated benefits and harms of OC use that are not related to the development of ovarian cancer. Finally, we designed a comparative effectiveness model to inform the questions generated by this review. The Key Questions considered in this review are: KQ1: What is the effectiveness of combined (estrogen and progestin containing) and progestin-only OCs for reducing the risk of ovarian cancer? KQ2: Do specifics of OC use (e.g., dose/formulation, age at initiation, duration of use) affect the relative risk of developing ovarian cancer? KQ3: Does the use of OCs by specific populations of women (e.g., those defined by age, family history of breast and ovarian cancer, BRCA1/BRCA2 mutation status, parity) affect the relative risk of developing ovarian cancer? KQ4: Aside from pregnancy prevention, are there other benefits of OC use in reducing the risks of endometrial cancer or colorectal cancer? KQ5: What are the harms of OC use, including breast cancer incidence, cervical cancer incidence, venous thromboembolic disease, stroke, or myocardial infarction? How do these harms vary by dose or formulation, duration of use, or specific population? KQ6: Based on the comprehensive literature review, what are the benefits and harms from the use of OCs to reduce the incidence of ovarian cancer for specific populations? Based on the decision model, what is the estimated effect of these benefits and harms on life expectancy and quality-adjusted life expectancy? KQ7: Based on the systematic review and decision model, what research gaps need to be filled to better understand whether OCs are effective for the primary prevention of ovarian cancer?
